- Home
- CCK vs EXAS Comparison
CCK vs EXAS Comparison
Compare CCK & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCK
- EXAS
- Stock Information
- Founded
- CCK 1906
- EXAS 1995
- Country
- CCK United States
- EXAS United States
- Employees
- CCK N/A
- EXAS N/A
- Industry
- CCK Containers/Packaging
- EXAS Medical Specialities
- Sector
- CCK Industrials
- EXAS Health Care
- Exchange
- CCK Nasdaq
- EXAS Nasdaq
- Market Cap
- CCK 11.2B
- EXAS 10.2B
- IPO Year
- CCK N/A
- EXAS N/A
- Fundamental
- Price
- CCK $95.32
- EXAS $53.59
- Analyst Decision
- CCK Strong Buy
- EXAS Strong Buy
- Analyst Count
- CCK 13
- EXAS 22
- Target Price
- CCK $121.23
- EXAS $67.38
- AVG Volume (30 Days)
- CCK 1.3M
- EXAS 2.7M
- Earning Date
- CCK 10-16-2025
- EXAS 11-04-2025
- Dividend Yield
- CCK 1.09%
- EXAS N/A
- EPS Growth
- CCK 31.02
- EXAS N/A
- EPS
- CCK 4.73
- EXAS N/A
- Revenue
- CCK $12,013,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- CCK $4.13
- EXAS $16.68
- Revenue Next Year
- CCK $2.73
- EXAS $12.08
- P/E Ratio
- CCK $20.13
- EXAS N/A
- Revenue Growth
- CCK 2.23
- EXAS 12.55
- 52 Week Low
- CCK $75.98
- EXAS $38.81
- 52 Week High
- CCK $109.48
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- CCK 41.62
- EXAS 60.65
- Support Level
- CCK $93.51
- EXAS $52.11
- Resistance Level
- CCK $96.76
- EXAS $56.52
- Average True Range (ATR)
- CCK 1.94
- EXAS 1.70
- MACD
- CCK 0.10
- EXAS 0.18
- Stochastic Oscillator
- CCK 40.81
- EXAS 71.33
About CCK Crown Holdings Inc.
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.